Drug Profile


Alternative Names: 17-Alpha estradiol; 17-α estradiol; Estrogen analogue - MIGENIX; MITO-4509; MX-4509

Latest Information Update: 08 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MIGENIX
  • Class Antidementias; Antiparkinsonians; Estradiol congeners; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Friedreich's ataxia; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 14 Dec 2005 A clinical study has been added to the adverse events and pharmacokinetics sections
  • 28 Apr 2005 MIGENIX receives clearance from Health Canada to conduct a phase I/II trial for Alzheimer's disease in Canada
  • 23 Feb 2005 Phase-I clinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top